Post Content
Is PGEN a good stock to buy? We came across a bullish thesis on Precigen, Inc. on Valueinvestorsclub.com by coalone. In this article, we will summarize the bulls’ thesis on PGEN. Precigen, Inc.’s share was trading at $4.0200 as of April 28th. PGEN’s forward P/E was 9.14 according to Yahoo Finance.
Pressmaster/Shutterstock.com
Precigen (PGEN) is a biotechnology company that has transitioned from a clinical-stage developer to a commercial rare disease platform following the August 2025 approval of Papzimeous for recurrent respiratory papillomatosis, positioning it as a newly commercial asset with significant re-rating potential as launch execution unfolds.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
The drug targets a 27,000-patient US RRP population and carries a $460,000 four-dose regimen delivered via buy-and-bill channels, but the early launch phase is constrained by insurance coverage variability, hospital onboarding, and reimbursement friction despite strong physician enthusiasm.
Market expectations appear significantly misaligned with real-world adoption, as care is concentrated in 100–150 specialist clinics treating a large share of high-severity patients, enabling efficient education and rapid protocol adoption supported by KOL advocacy and increasing appeal success rates. Modeling suggests only a fraction of patients are currently treated, yet conservative projections indicate roughly 1,600–1,700 patients in 2026 and nearly 3,000 in 2027, with dosing-based revenue recognition driving pronounced quarterly volatility and setting up for significant revenue surprises.
This dynamic supports expectations for outsized quarterly beats of 100%+ to 300%+ in 2026, potential EPS inflection into profitability, and multiple valuation frameworks converging on substantial upside through SOTP rerating, forward earnings expansion, and NPV-based long-term cash flow potential across RRP and HPV indications.
Strategically, the platform also embeds meaningful acquisition optionality, with large-cap pharma such as Merck viewed as potential acquirers given HPV oncology expansion, ex-US commercialization leverage, and manufacturing scale, supporting a long-term takeout narrative potentially valuing the company near $20 per share by 2027 target premium.
Previously, we covered a bullish thesis on CRISPR Therapeutics AG (CRSP) by MADD-Scientis in March 2025, which highlighted Casgevy-driven commercialization, gene-editing pipeline optionality, and strong reimbursement progress supporting multi-billion-dollar long-term upside. CRSP’s stock price has appreciated by approximately 27.06% since our coverage. Magnus Ofstad shares a similar view but emphasizes Sarepta Therapeutics’ (SRPT) acquisition-driven rerating potential within rare disease leadership.